Revolutionary New Cervical Cancer Screening Test to Hit Worldwide Market
Company to Attend American Congress of Obstetricians and Gynecologists 60th Annual Meeting in San Diego, California; Doctor Roy Mora, Inventor of Citofem, Wins the Silver Medal in the World Inventors Expo in Geneva, Switzerland
(firmenpresse) - LITTLE ROCK, AR -- (Marketwire) -- 05/02/12 -- Biodis, an international biotechnology distributor, announced today that the company will begin their new product launch of Citofem® in North America, India, Africa and Asia.
"There are only two major pap smear products on the market today, now with Citofem®, there is a third. This Pap test kit however, offers the highest sensitivity at the lowest price, making this a powerful weapon in the battle against cervical cancer worldwide," said Kent Erickson, Vice President of Sales for North America.
Citofem® achieves the same superior results of all liquid cytology products. But, the Citofem approach includes a very simple manual procedure for sample preparation that eliminates the need to purchase costly equipment. Analysis requires no specialized training, and requires no additional purchases of related laboratory equipment or supplies. All that is needed to carry out the tests is found in the kit provided by Citofem® at a price comparable to the traditional Pap test. The process is extremely efficient with a single cytotechnologist processing on average over 750 slides per day.
"Citofem results in a significant reduction in false negatives, increasing the diagnosis of the disease in its early stages," said Dr. Ladly Abraham, Chief Medical Officer of Biodis. "Citofem is also responsible for a reduction in inconclusive results arising from atypical squamous cells (ASC). It also results in the increased level of detection of low grade squamous intraepithelial lesions (LSIL) and high-grade squamous intraepithelial lesions (HSIL). We're very excited about Citofem because it's the most complete system for the early detection of cervical cancer, in that it obtains a much higher population of endocervical cells in the sample."
Most Affordable Alternative
Captures 100% of cells; 2x-3x more endocervical cells captured
Xylene Free making it the most "green" pap test on the market
Multiple slides per patient
Exclusive Rovers Combi Cervix-Brush
60% of blood and mucus removed
Cubliq liquid cover slip
All-Inclusive kit (brush, slides and reagents)
HPV and Chlamydia testing
Histo-chemical immunology testing without a 2nd patient sample
About Biodis
Biodis is dedicated to delivering the vital medicines, medical supplies and information technologies that enable the health care industry to provide patients better, safer care.
Our customers include hospitals, clinics, state health associations, group purchasing organizations, national and local pharmacies, manufacturers, and insurers.
Biodis is one of the emerging biotechnology distributors in the world. We act as one of the primary international distributors of multiple products produced by BioTD and other manufacturers.
For Additional information on this announcement, please contact:
Kent Erickson
(501) 868-8300
email address:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 02.05.2012 - 10:44 Uhr
Sprache: Deutsch
News-ID 1109849
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
LITTLE ROCK, AR
Phone:
Kategorie:
Health & Nutrition
Anmerkungen:
Diese Pressemitteilung wurde bisher 108 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Revolutionary New Cervical Cancer Screening Test to Hit Worldwide Market
"
steht unter der journalistisch-redaktionellen Verantwortung von
Biodis (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
